WinSanTor, with feeling

WinSanTor is inhibiting muscarinic receptors for diabetic neuropathy

The founders of WinSanTor Inc. have discovered that the muscarinic antagonist pirenzepine can stimulate peripheral nerve growth and function and treat a preclinical model of diabetic neuropathy as a topical agent. The company has started a Phase I trial of the compound in the indication, and expects to initiate Phase II this year.

Although pirenzepine, a generic inhibitor of the muscarinic acetylcholine receptor M1 (CHRM1; HM1), is approved in Europe for treating ulcers, it has

Read the full 757 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE